Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 Inhibitors

被引：5
|
作者：
Kazi, Dhruv S. [1 ]
Penko, Joanne [1 ]
Ollendorf, Daniel A. [2 ]
Coxson, Pamela G. [1 ]
Bibbins-Domingo, Kirsten [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Inst Clin & Econ Review, Boston, MA USA
来源：
ANNALS OF INTERNAL MEDICINE | 2018年 / 168卷 / 12期
关键词：
D O I：
10.7326/M17-3367
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：896 / +
页数：3
相关论文
共 50 条
  • [31] The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice
    Bradley, Corey K.
    Shrader, Peter
    Sanchez, Robert J.
    Peterson, Eric D.
    Navar, Ann Marie
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) : 725 - 734
  • [32] The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia
    Tziomalos, Konstantinos
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (10) : 1495 - 1499
  • [33] Update on proprotein convertase subtilisin/kexin type 9 inhibitors, lipoprotein(a) and cardiovascular risk
    Martinez, Laurent O.
    Perret, Bertrand
    Genoux, Annelise
    CURRENT OPINION IN LIPIDOLOGY, 2021, 32 (05) : 324 - 327
  • [34] The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
    Ben Zadok, O. Itzhaki
    Mager, A.
    Leshem-Lev, D.
    Lev, E.
    Kornowski, R.
    Eisen, A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1828 - 1828
  • [35] Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Shahreyar, Muhammed
    Salem, Salem A.
    Nayyar, Mannu
    George, Lekha K.
    Garg, Nadish
    Koshy, Santhosh K. G.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) : 628 - 634
  • [36] Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner, Vera
    CIRCULATION, 2016, 134 (22) : 1695 - 1696
  • [37] Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
    Muhammad Shafiq
    Timothy Walmann
    Venkat Nutalapati
    Cheryl Gibson
    Yousaf Zafar
    World Journal of Hepatology, 2020, 12 (12) : 1258 - 1266
  • [38] Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
    Shafiq, Muhammad
    Walmann, Timothy
    Nutalapati, Venkat
    Gibson, Cheryl
    Zafar, Yousaf
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (12) : 1258 - 1266
  • [39] Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology
    Mahmood, Tahir
    Shapiro, Michael D.
    CURRENT OPINION IN CARDIOLOGY, 2019, 34 (05) : 519 - 525
  • [40] Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Fatty Infiltration of the Liver
    Shafiq, Muhammad
    Walmann, Timothy
    Nutalapati, Venkat
    Gibson, Cheryl
    Zafar, Yousaf
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1712 - S1712
12345